NF-κB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth

Shannon T. Bailey1,2, Penelope L. Miron3, Yoon J. Choi3, Bose Kochupurakkal3, Gautam Maulik, Scott. J. Rodig5, Ruiyang Tian3, Kathleen M. Foley3, Teresa Bowman4, Alexander Miron3, Myles Brown1,5, J. Dirk. Iglehart3,4, and Debajit K. Biswas3,4

Abstract

Breast cancers with HER2 overexpression are sensitive to drugs targeting the receptor or its kinase activity. HER2-targeting drugs are initially effective against HER2-positive breast cancer, but resistance inevitably occurs. We previously found that NF-κB is hyperactivated in a subset of HER2-positive breast cancer cells and tissue specimens. In this study, we report that constitutively active NF-κB rendered HER2-positive cancer cells resistant to anti-HER2 drugs and cells selected for lapatinib resistance upregulated NF-κB. In both circumstances, cells were antiapoptotic and grew rapidly as xenografts. Lapatinib-resistant cells were refractory to HER2 and NF-κB inhibitors alone but were sensitive to their combination, suggesting a novel therapeutic strategy. A subset of NF-κB-responsive genes was overexpressed in HER2-positive and triple-negative breast cancers, and patients with this NF-κB signature had poor clinical outcome. Anti-HER2 drug resistance may be a consequence of NF-κB activation, and selection for resistance results in NF-κB activation, suggesting that this transcription factor is central to oncogenesis and drug resistance. Clinically, the combined targeting of HER2 and NF-κB suggests a potential treatment paradigm for patients who relapse after anti-HER2 therapy. Patients with these cancers may be treated by simultaneously suppressing HER2 signaling and NF-κB activation.

Implications: The combination of an inhibitor of IκB kinase (IKK) inhibitor and anti-HER2 drugs may be a novel treatment strategy for drug-resistant human breast cancers. Mol Cancer Res; 12(3); 408–20. ©2013 AACR.

Introduction

Diverse histopathology and clinical manifestations of breast cancer are linked to hormone and growth factor-mediated cellular and molecular pathways (1). For therapeutic and prognostic purposes, human breast cancers are subclassified on the basis of their hormone and growth factor receptor expression. One subclass is defined by amplification of the HER2 protein, which is encoded by the ERBB2 gene. This protein is a member of the EGF receptor (EGFR) family (2, 3) and lacks a ligand-binding domain; thus, its signals are propagated by dimerization with other ligand-bound EGFR family members to form a signaling complex (2, 4–6). HER2 kinase activation leads to the stimulation of downstream signaling, which is mediated by the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways (4, 5, 7). Elevated HER2 protein expression magnifies its kinase activity, leading to a cellular dependence on HER2 signaling and sensitivity to HER2-targeted therapies (2, 8–12). HER2 inhibition is an effective treatment for patients with HER2-positive breast cancers. Trastuzumab, a humanized monoclonal antibody directed against the HER2 extracellular domain, has been used as first-line therapy for HER2-positive breast cancers. The supplementation of chemotherapy with trastuzumab increases the survival time of patients with metastatic HER2-positive disease, and its addition to standard treatment reduces the odds of recurrence by 50% (9, 13). Lapatinib, which is a highly effective small-molecule inhibitor of HER2 tyrosine kinase activity (7), was first used in clinical trials in 2005 (5). Resistance to lapatinib therapy has been reported to be common and may be due to activation of compensatory growth factor pathways (14).

In certain breast cancers, HER2 signaling leads to stimulation of the NF-κB transcription factor pathway (15, 16). The NF-κB transcription factor is a dimeric complex of rel family proteins that is sequestered in its basal state in the cytoplasm with inhibitor of NF-κB (IκB) proteins. Classical

Note: Supplementary data for this article are available at Molecular Cancer Research Online (http://mcr.aacrjournals.org/).

S.T. Bailey, P.L. Miron, and Y.J. Choi contributed equally to this work.

J.D. Iglehart and D.K. Biswas are senior authors and contributed equally to this work.

Corresponding Author: Debajit K. Biswas, Department of Cancer Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Smith 958, Boston, MA 02215; Phone: 617-632-4884; Fax: 617-632-3709; E-mail: debajit_biswas@dfci.harvard.edu or dkbmbm@gmail.com

doi: 10.1158/1541-7786.MCR-13-0206-T

©2013 American Association for Cancer Research.
NF-κB activation is initiated by cell surface receptors responding to a variety of diverging stimulants, leading to signal propagation that ultimately activates the inhibitor of IκB kinase (IKK) complex (17). The IKK complex consists of two catalytic subunits, IKKα and IKKβ, and one regulatory subunit, IKKγ (also known as NF-κB essential modulator; NEMO; ref. 11). This complex phosphorylates IκB, leading to its degradation and the release of NF-κB, allowing this transcription factor to translocate into the nucleus and transactivate target genes. The inhibition of IKK or HER2 by specific inhibitors blocks NF-κB activation (12). NF-κB activation was linked to human breast cancer in studies demonstrating the nuclear localization of NF-κB family proteins in breast cancer cell lines and patient tissue (18).

Mammary gland epithelial hyperplasia and ductal branching is increased in mice lacking the IκBα protein, and development is impaired by NF-κB signaling pathway interference (19). Mice with mouse mammary tumor virus (MMTV)–driven c-rel develop late-onset mammary carcinomas of various pathologies (20). The stimulation of EGFR family receptors with EGF or heregulin (HRG) results in NF-κB activation in breast cancer cells, and inhibition of the IKK complex blocks NF-κB activation and xenograft outgrowth (12, 16). Active NF-κB signaling is present in estrogen receptor (ER)-negative breast cancers, including triple-negative and HER2-positive subtypes (16, 18), its activation is a natural apoptosis inhibitor, and the inhibition of NF-κB activation induces apoptosis in breast cancer cells, leading to tumor regression (21).

In this study, we examine the oncogenic role of HER2-induced NF-κB signaling in a clonal derivative (SKR6) of the HER2-positive, ER-negative human breast cancer cell line SKBR3. SKR6 cells expressing constitutively activated NF-κB are resistant to anti-HER2 drugs, and NF-κB is overactivated in lapatinib-resistant SKR6 cells. In both cell types with overactivated NF-κB, apoptosis is blocked profoundly and both rapidly generate xenografts. A set of genes overexpressed in both cell types is identified as a consequence of NF-κB overactivation. The SKR6 cells expressing constitutively activated NF-κB and lapatinib-resistant SKR6 cells express a common antiapoptotic gene set that is also found in tumors from patients with poor outcome.

Materials and Methods

Cell lines and nomenclature

The nomenclature of the SKBR3 [from American Type Culture Collection (ATCC)] and derivatives are as follows: (i) SKR6, a clonal derivative of SKBR3 cells that was isolated by fluorescence-activated cell sorting (FACS) to enrich for elevated HER2 levels. (ii) SKR6CA, SKR6 cells that were retrovirally transduced with constitutively active NF-κB relA/p65 (CAP65; ref. 22). (iii) SKR6-Vector, SKR6 cells that were transduced with the pQCXIP empty retroviral vector and selected with puromycin. (iv) SKR6LR, SKR6 cells that were treated with increasing lapatinib concentrations from 0.2 to 5 μmol/L for several months. Cells were maintained in RPMI-1640 supplemented with 10% FBS and antibiotics (rich medium). Minimal medium was RPMI-1640, phenol red–free supplemented with dextran-coated charcoal-treated FBS (HyClone, Inc.). The resistant cells were subsequently maintained under standard culture conditions in the presence of 0.2 μmol/L lapatinib. The genetic identity of the SKBR3 and derivative cell lines was confirmed by DNA fingerprinting with short-tandem repeats (STR), which was performed in the Dana-Farber Cancer Institute (Boston, MA) Molecular Diagnostic Core facility. The cell lines were grown in rich or minimal medium as previously described (12).

Reagents

The HRG β1 and anti-actin antibodies were purchased from Sigma. Trastuzumab, the humanized anti-HER2 antibody (Herceptin; Genentech), was obtained from the Dana-Farber Cancer Institute pharmacy. The anti-HER2 and anti-IκBα antibodies were obtained from Cell Signaling Technology. The anti-relA (p65; sc-8008) antibody was obtained from Santa Cruz Biotechnology. Lapatinib was purchased from Fisher Scientific. The NEMO-binding domain (NBD) peptide (11, 23) was synthesized at the Dana-Farber Cancer Institute core facilities. Matrigel High Concentration (HC) was obtained from BD Biosciences. The retroviral vector pQCXIP-CAP65 (22) was a generous gift from Drs. Harikrishna Nakshatri and Poornima Bhat-Nakshatri of the Department of Surgery, Indiana University School of Medicine (Indianapolis, IN).

NF-κB activation assay

The activity of NF-κB was determined in nuclear extracts by electrophoretic mobility shift assay (EMSA) as described previously (12, 16). NF-κB activation was also determined by nuclear translocation of NF-κB p65 by immunofluorescence (16).

Xenograft growth

Approximately, 3 to 6 × 10⁶ cells were suspended in 0.25 mL of sterile PBS, thoroughly mixed with 0.25 mL Matrigel (BD Biosciences), and implanted under the dorsal skin of 6-week-old female nu/nu mice (NCR NUM Homozygous; Taconic). Tumor growth was monitored weekly by measuring its dimensions, and the tumor volume was calculated by using the following formula: \( V = \frac{1}{2} \times \text{SS} \times \text{LS} \times 0.41 \), where SS = short side and LS = long side (24).

FACS analysis of HER2 levels

Approximately, 1 × 10⁶ cells were incubated with humanized anti-HER2 antibody (Herceptin) followed by incubation with fluorescein isothiocyanate (FITC)–conjugated goat anti-human immunoglobulin G (IgG). Cells incubated with secondary antibody alone served as a control for nonspecific binding and auto-fluorescence signals from the FACS analysis.

Chromatin immunoprecipitation assay

Chromatin immunoprecipitation (ChIP) was performed as previously described (25). Briefly, approximately 5 × 10⁶ SKBR-3 cells were seeded in hormone-depleted media. After 3 days, the cells were treated with 10 μmol/L HRG in the...
absence and presence of 10 μmol/L NBD for 40 minutes. The cells were cross-linked for 10 minutes at room temperature with 1% formaldehyde, which was then quenched with 0.125 mol/L glycine for 5 minutes. The cells were washed in PBS and then lysed in 1% SDS lysis buffer and sonicated. The fragmented chromatin was immunoprecipitated overnight using an antibody directed against p65 (C-20; Santa Cruz Biotechnology). The DNA was then purified using the QIAquick PCR Purification Kit (Qiagen), and the samples were subjected to real-time PCR (RT-PCR) using the Power SYBR Green PCR Master Mix (Applied Biosystems). The NF-κB targets were subjected to real-time PCR using the primers corresponding to NF-κB (Tabchy and colleagues (39), Waddell and colleagues (40), Minn and colleagues (37), Richardson and colleagues (38), Tabchy and colleagues (39), Waddell and colleagues (40), and The Cancer Genome Atlas (TGCA; ref. 1; http://cancergenome.nih.gov)). Kaplan–Meier was performed to determine the survival of patients in the Kao dataset using the survival package in R version 2.15.2. The significance of the difference between the survival curves was calculated using the log-rank test.

**Results**

**Functional assessment of NF-κB activation in parental SKBR3 and derivatives**

Nuclear localization of relA, the p65 NF-κB subunit, indicates activation of the NF-κB pathway. As expected, SKBR3 cells grown in rich medium harbored nuclear p65 and prominent HER2 membrane staining (Fig. 1A). Culturing SKBR3 cells in hormone and growth factor–depleted media leads to the translocation of p65 into the cytoplasm. Treatment with HG, a HER2 agonist, but not vehicle (dimethyl sulfoxide, DMSO) leads to the translocation of p65 into the nucleus (Fig. 1B, top and middle). NF-κB activation was blocked by treatment with the NBD peptide, which inhibits the IKK complex, confirming NF-κB activation following HER2 stimulation by HRG (Fig. 1B, bottom).

Next, we examined the level of basal and activated NF-κB in SKBR3 cells by DNA-binding activity using an EMSA. In agreement with the immunofluorescence results, we observed a NF-κB mobility shift in nuclear extracts from SKBR3 cells grown in rich media. The level of NF-κB DNA-binding activity was reduced in cells grown in minimal media, and binding was elevated in the presence of HRG. This binding was reduced when cells were treated with HRG in the presence of NBD (Fig. 1C).

We confirmed these data with a ChIP assay in which the level of NF-κB p65 binding was measured in the presence and absence of HRG plus and minus NBD. Increased p65 binding was found at NF-κB–binding sites in NF-κB–responsive genes in the presence of HER2 stimulation. Binding was reduced when cells were treated with HRG in the presence of NBD (Fig. 1D). The ChIP data validate the EMSA results and demonstrate that NF-κB is under the control of HER2 signaling, and its activation is mediated via the IKK complex in the SKBR3 cells.
Different HER2 protein levels in SKBR3 cells may lead to different oncogenic potentials. Heterogeneity in nonclonal populations may obscure these differences. Thus, we sorted SKBR3 cells to select for a fraction expressing elevated HER2 levels and derived a single-cell clone from this fraction to acquire a population with stable and uniform elevated HER2 expression, which we designated SKR6 (Supplementary Fig. S1). The SKR6 clone was then transduced with a control virus or retrovirus encoding constitutively activated NF-κBp65 (Cap65) to create SKR6-Vector and SKR6CA cells, respectively. As expected, the SKR6CA cells demonstrated elevated and persistent NF-κB DNA-binding activity under all culture conditions, demonstrating its constitutive activity. The SKR6 and SKR6-Vector cells exhibited regulated NF-κB activity that was similar to the parental SKBR3 cells. The stable lapatinib-resistant cell clone SKR6LR, which was selected from SKR6 cells by long-term, stepwise lapatinib treatment (0.25–5 μmol/L), maintained elevated NF-κB activity in rich and minimal media containing vehicle or HRG. However, treatment with NBD blocked the elevated NF-κB activity in SKR6LR cells, suggesting that lapatinib resistance involves a step upstream of the IKK complex (Fig. 1E).

**NF-κB Activation Underlies Anti-HER2 Resistance**

We analyzed the influence of trastuzumab, lapatinib, and NBD on the viability of the SKR6 and derivative cell lines. Parental SKR6 cells are sensitive to all three drugs, whereas SKR6CA and SKR6LR cells are resistant to these drugs (Fig. 2A–C). Treatment of SKR6LR cells with increasing doses of lapatinib reduced the level of HER2 phosphorylation immediately downstream of HER2 activation in a dose-responsive manner.
fashion. The identical dose-response pattern was observed in SKR6 cells (Supplementary Fig. S2). This result demonstrates that resistance to lapatinib is not explained by the inability of the drug to inhibit the tyrosine kinase activity of the HER2 protein or by alteration of HER2 signaling at the initial step of HER2 phosphorylation.

Treatment with NBD alone leads to only a 17% reduction in cell viability in SKR6LR cells at a concentration of 100 μmol/L; lower NBD concentrations had no effect (Fig. 2C). In SKR6LR cells, lapatinib at a concentration of 500 nmol/L had no effect on cell viability. However, increasing concentrations of NBD in combination with a constant dose of lapatinib (500 nmol/L) led to a dose-dependent decrease in cell viability, which was consistently observed at NBD doses as low as 10 μmol/L (Fig. 2D). These results suggest a potential role for NF-κB inhibition combined with HER2 suppression in lapatinib-resistant breast cancer.

NF-κB activity promotes xenograft growth and is antiapoptotic in tumors

Parental SKBR3 cells and SKR6 cell derivatives were tested for their ability to grow as xenografts in nu/nu mice. Although parental SKBR3 xenografts did not grow for up to 20 weeks, HER2-enriched SKR6 xenografts were palpable by 6 weeks with a moderate increase in tumor volume over 20 weeks (Fig. 3A). In contrast, SKR6CA xenografts grew rapidly and reached the maximum size allowable by 20 weeks (Fig. 3B). SKR6LR xenografts grew with comparable kinetics to SKR6CA xenografts, reaching maximal size by 20 weeks (Fig. 3C). The SKR6, SKR6CA, and SKR6LR cell lines formed high-grade tumors with large nuclei, prominent nucleoli, numerous mitotic cells, and large nests of dense tumor cells with central necrosis. Smaller nests of tumor cells with lower tumor cellularity and no necrosis were found in SKR6 xenografts (Supplementary Fig. S3).

The enrichment of HER2 in SKR6 cells promoted tumor growth, and SKR6 cells contained elevated NF-κB activity compared with SKBR3 parental cells (Supplementary Fig. S4A). SKR6CA and SKR6LR cells and xenografts displayed very elevated NF-κB activity, which was much higher than that observed in SKR6 cells or xenografts (Supplementary Fig. S4A and S4B). A stepwise increase in HER2 levels in SKBR3, SKR6, and SKR6CA leads to elevated NF-κB activity, suggesting that HER2 connects to the NF-κB transcriptional machinery. Constitutively active NF-κB leads directly to increased xenograft growth, tumor necrosis,
and HER2-directed drug resistance. Cells selected for lapatinib resistance grew rapidly as xenografts and displayed levels of NF-κB activation equivalent to SKR6CA.

The fraction of apoptotic tumor cells measured by TUNEL staining in tumor sections was captured and quantified. Parental SKR6 xenografts demonstrated a mixed proportion of apoptotic and nonapoptotic cells (Fig. 3D). In contrast, there was a dramatic absence of TUNEL-positive cells in tissue sections from SKR6CA and SKR6LR xenografts (Fig. 3E and F). The absence of apoptosis correlates with the increase in NF-κB activity observed in SKR6CA and SKR6LR xenografts. In SKR6 tumors, approximately 60% of the cells in multiple tumors and a variety of sections from the same tumor were TUNEL-positive. In contrast, SKR6CA and SKR6LR xenografts both displayed less than 10% TUNEL-positive cells (Fig. 3G). The antiapoptotic state of the SKR6LR cells was strikingly similar to that of the SKR6CA cells, implying that NF-κB activation is responsible for the antiapoptotic state of tumors derived from lapatinib-resistant cells.

**Effect of combined HER2 and NF-κB inhibition on apoptosis in drug-resistant cells**

Because lapatinib and NBD combined treatment retarded the growth of SKR6LR cells and overcame resistance, we examined this dual targeting strategy and its effect on apoptosis. We treated the SKBR3 derivative cells with vehicle, NBD, lapatinib, and NBD plus lapatinib and measured apoptosis using Annexin V binding and TUNEL assays. Although we observed an increase in Annexin V

---

**Figure 3.** Xenograft growth and apoptotic fractions of SKBR3 and its derivatives. A, growth of SKBR3 or its HER2-enhanced clonal derivative SKR6. B, SKR6CA. C, SKR6LR. A total of $3 \times 10^7$ cells were suspended in 0.25 mL PBS mixed with 0.25 mL of Matrigel and implanted subcutaneously on the dorsal surface of nu/nu mice. Tumor volume was measured weekly; error bars are 1 SD of the mean of 10 tumors. At 8 to 10 weeks, tumors from SKR6CA and SKR6LR cells, and at 17 weeks tumors from SKR6 were excised, formalin-fixed and paraffin-embedded. Sections were stained with ApopTag for apoptotic nuclei. Representative images are shown at ×1.5 magnification, and expanded to ×20 to visualize the apoptotic fraction. D, representative section from SKR6 xenografts. E, representative section from SKR6CA xenografts. F, representative section from SKR6LR xenografts. G, mean apoptotic fractions from SKR6, SKR6CA, and SKR6LR xenografts were determined by analysis of five independent sections from each of three tumors quantified by image analysis. Error bars are 1 SD of the mean apoptotic fraction.
binding in SKR6 cells in response to all treatments, cells treated with NBD plus lapatinib demonstrated the highest level of apoptosis. As expected, SKR6CA cells maintained low apoptotic levels during all treatments (Fig. 4A). In the SKR6LR cells, we observed little to no apoptosis in the presence of NBD or lapatinib alone, whereas treatment with both compounds (10 μmol/L NBD plus 100 nmol/L lapatinib) led to a dramatic increase in apoptosis (Fig. 4A). In addition, TUNEL staining demonstrated massive apoptosis only in SKR6LR cells treated with combined HER2 and NF-κB inhibition (Fig. 4B and C).

Expression profiles of activated NF-κB and lapatinib-resistant cell lines

We performed expression analysis to interrogate genes that are differentially expressed in SKR6-Vector compared with SKR6CA cells and SKR6 compared with SKR6LR cells. We found 969 genes differentially expressed in SKR6CA compared with SKR6-Vector cells and 4,563 genes differentially expressed in SKR6LR compared with SKR6 cells with a 2-fold difference and \( P < 0.01 \). Comparison of the genes regulated in each analysis revealed 603 genes in common (Fig. 5A).

The 603 common genes were grouped by hierarchical clustering into four main clusters (Fig. 5B). We next performed GO analysis within each of the clusters to determine the biologic processes influenced by the differentially expressed genes. Cluster I is composed of genes upregulated in SKR6CA and SKR6LR cells. This cluster is enriched for pathways associated with the negative regulation of programmed cell death and apoptosis in addition to genes associated with pathways regulated by NF-κB signaling (Fig. 5C). GO analysis of genes in clusters II–IV did not reveal strong associations with apoptosis or cell death (Supplementary Fig. S5). Because the relative overexpression of cluster I genes is consistent with the loss of apoptosis observed in SKR6CA and SKR6LR cells and xenografts, we focused on these genes for further analysis.

Interrogation of human breast cancer datasets

Oncomine is a collection of gene expression datasets derived from patients with cancer and includes analysis tools (41). Using Oncomine, we performed a molecular concepts analysis of the list of cluster I genes to determine whether these genes were also overexpressed in tumor samples derived from patients with breast cancer. We found that cluster I genes were significantly overexpressed in tumors from patients with HER2-positive and triple-negative breast cancers (Fig. 6A). Cluster I overexpression in HER2-positive breast cancer agrees with the findings reported in this study.
Relatively elevated NF-κB activity is also observed in triple-negative breast cancer cell lines and tumors (16, 42). The overexpression of cluster I genes in many triple-negative datasets from clinical samples suggests that NF-κB may be active in this subset as well.

Heatmaps demonstrate the relative difference in the expression of cluster I genes in HER2-negative versus HER2-positive tumors. There was an overall relative down-regulation of expression of cluster I genes in HER2-negative tumors compared with those that were HER2-positive (Fig. 6B). The Kao breast cancer dataset contains gene expression data from 327 breast tumors from Taiwanese patients and is balanced for the content of HER2-positive, triple-negative, and ER-positive cancers. In this dataset, the HER2-negative tumors that were also characterized as negative for ER and PR (triple-negative) exhibited overexpression of cluster I genes (Fig. 6B). These data are in agreement with the heatmaps that include datasets comparing cluster I gene expression in tumors that are triple-negative versus those that possess some other biomarker status (Fig. 6C).

Finally, we explored the association of cluster I genes with patient outcome. Because treatments varied over time and across institutions contributing tumor expression data, we simply asked whether cluster I genes were statistically associated with tumors from patients who suffered a poor outcome, which is defined as having a metastatic event, recurrence, or death within 1 to 5 years of diagnosis. Each dataset was analyzed separately. We found that cluster I gene overexpression is commonly enriched in tumors from patients with poor outcome (Table 1). In addition, Kaplan–Meier analysis of patients with HER2-positive and triple-negative tumors in the Kao dataset demonstrates that those whose tumors contain high expression of cluster I genes have worse overall survival than those with low expression of these genes (Fig. 6D). We propose that the poor clinical outcome of patients with tumors enriched for
overexpressed cluster I genes are at least partially a consequence of NF-κB activation.

**Discussion**

The oncogenic potential of HER family receptors in breast cancer has been studied in great depth (20, 43). In most of these studies, genetic manipulations were used to enhance HER family receptor-mediated signaling (12). The primary goal of this study was to explore connections between HER2 and NF-κB in HER2-positive breast cancer cells. We wanted to explore consequences of NF-κB activation, therapeutic opportunities for inhibitors, and potential pathways of resistance to HER2-directed drugs. In our previous studies, we included several other HER2-positive cell lines, but decided to explore a single HER2-positive line, SKBR3, and acquire several derivatives of these cells. In particular, we derived a homogeneous clone of SKBR3 selected for uniform HER2 expression, engineered a derivative of this clone with constitutively active NF-κB, and selected a line resistant to lapatinib, a potent inhibitor of HER2 and EGFR. HER2 enrichment was achieved by FACS and subsequent cloning by serial dilution. Significantly, the enhanced HER2

Figure 6. Cluster I genes overexpressed in SKBR6CA and SKBR6LR are associated with HER2-positive and triple-negative human breast cancer. A, Oncomine Concepts Map analysis (https://www.oncomine.com). Cluster I genes were interrogated in publicly available primary breast tumor gene expression datasets to determine significant overexpression in tumor subsets. These associations were represented in a network using Cytoscape (http://www.cytoscape.org). In this network, edges connect datasets that are significantly associated with cluster I genes (shown in blue). Significant associations were found with datasets from patients with triple-negative breast cancer (red circles) and those with HER2-positive breast cancer (green circles). Each node size is proportional to the number of patients demonstrating association in each dataset. B, heatmaps of the Kao, Lu, and Richardson datasets [shown as green nodes in (A)] demonstrate the relative expression of the cluster I genes in HER2-positive versus HER2-negative patients (Materials and Methods for references). C, heatmaps of cluster I gene expression in the TCGA, Waddell, and Gluck breast datasets, representative of the HER2/ER/PR-negative datasets [triple-negative, are shown as red nodes in (A)] demonstrate their relative expression in HER2/ER/PR-negative patients. D, Kaplan–Meier analysis of the probability of overall survival in HER2-positive and HER2/ER/PR-negative patients based on expression of cluster I genes, dichotomized by the median gene expression into high and low expression groups. The P value was calculated with the log-rank test.
expression in the cloned derivative, SKR6, was stable in nearly continuous passage for 1 year (Supplementary Fig. S1). This clone generated xenografts in immunocompromised mice readily, whereas the parental SKBR3 cell line acquired from ATCC for these studies was only weakly tumorigenic.

The HER2-enriched SKR6 cells also harbored elevated levels of NF-κB activity, measured by DNA binding when compared with the originating SKBR3 cell line (Supplementary Fig. S4). We previously demonstrated that the heterodimeric NF-κB p50/p65 complex is the predominant NF-κB transcription complex bound to DNA in SKBR3 cells, and confirmed the presence of p65 by ChIP in these same cells (Fig. 1D). Xenografts derived from SKR6 cells also contain considerable NF-κB DNA-binding activity, which was greater than an equivalent extract from SKBR3 parental cells growing in culture (Supplementary Fig. S4). In cell lines, HRG stimulation of HER2 signaling results in NF-κB activation, which is blocked entirely by the specific inhibition of IKK by the NBD peptide (Fig. 1A). These observations are consistent with a role for NF-κB in the enhanced tumor-forming capability of SKR6 cells, which is likely a consequence of elevated HER2 protein levels in these cells. Furthermore, anti-HER2 drugs blocked NF-κB activation in SKBR3 cells, mirroring the effects of an IKK specific inhibitor (13). Signals that funnel through the IKK complex to activate NF-κB seem to be the predominant mechanism of connection between HER2 and NF-κB.

Our studies emphasize the importance of IKK in transmitting growth and antiapoptotic signaling from HER2. We selected a derivative of SKR6 cells, SKR6LR, which is resistant to the dual HER2/EGFR tyrosine kinase inhibitor lapatinib. Lapatinib is capable of completely blocking HER2 mitting growth and antiapoptotic signaling from HER2. We selected a derivative of SKR6 cells, SKR6LR, which is resistant to the dual HER2/EGFR tyrosine kinase inhibitor lapatinib. Lapatinib is capable of completely blocking HER2.

### Table 1. Cluster I genes associated with poor outcome

<table>
<thead>
<tr>
<th>Concept name</th>
<th>No. of overlap genes</th>
<th>P value</th>
<th>Q value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metastatic event at 3 years [Kao et al. (34)]</td>
<td>72</td>
<td>3.1E−10</td>
<td>5.4E−08</td>
</tr>
<tr>
<td>Metastatic event at 3 years [Bos et al. (44)]</td>
<td>64</td>
<td>3.1E−07</td>
<td>2.2E−05</td>
</tr>
<tr>
<td>Dead at 3 years [Kao et al. (34)]</td>
<td>63</td>
<td>6.8E−07</td>
<td>4.1E−05</td>
</tr>
<tr>
<td>Metastatic event at 3 years [Symmans et al. (45)]</td>
<td>53</td>
<td>1.1E−06</td>
<td>6.1E−05</td>
</tr>
<tr>
<td>Metastatic event at 1 year [Hatzis et al. (33)]</td>
<td>33</td>
<td>1.8E−06</td>
<td>9.3E−05</td>
</tr>
<tr>
<td>Metastatic event at 5 years [Kao et al. (34)]</td>
<td>61</td>
<td>3.1E−06</td>
<td>1.4E−04</td>
</tr>
<tr>
<td>Recurrence at 5 years [Ma et al. (46)]</td>
<td>54</td>
<td>7.3E−06</td>
<td>3.1E−04</td>
</tr>
<tr>
<td>Dead at 5 years [Boersma et al. (47)]</td>
<td>31</td>
<td>1.3E−05</td>
<td>5.0E−04</td>
</tr>
<tr>
<td>Recurrence at 1 year [Sorlie et al. (48)]</td>
<td>21</td>
<td>3.4E−05</td>
<td>1.0E−03</td>
</tr>
<tr>
<td>Metastatic event at 3 years (van’t Veer et al.)</td>
<td>43</td>
<td>3.7E−05</td>
<td>1.0E−03</td>
</tr>
<tr>
<td>Dead at 3 years [Sorlie et al. (49)]</td>
<td>32</td>
<td>5.2E−05</td>
<td>2.0E−03</td>
</tr>
<tr>
<td>Metastatic event at 3 years [Hatzis et al. (33)]</td>
<td>48</td>
<td>5.3E−05</td>
<td>2.0E−03</td>
</tr>
<tr>
<td>Recurrence at 1 year [Sorlie et al. (49)]</td>
<td>31</td>
<td>1.3E−04</td>
<td>3.0E−03</td>
</tr>
<tr>
<td>Dead at 1 year [Sorlie et al. (48)]</td>
<td>31</td>
<td>1.6E−04</td>
<td>4.0E−03</td>
</tr>
<tr>
<td>Metastatic event at 3 years [Minn et al. (37)]</td>
<td>46</td>
<td>2.1E−04</td>
<td>5.0E−03</td>
</tr>
<tr>
<td>Recurrence at 3 years [Sorlie et al. (48)]</td>
<td>19</td>
<td>3.0E−04</td>
<td>6.0E−03</td>
</tr>
<tr>
<td>Metastatic event at 3 years [Desmedt et al. (50)]</td>
<td>45</td>
<td>4.1E−04</td>
<td>8.0E−03</td>
</tr>
<tr>
<td>Dead at 1 year [Sorlie et al. (49)]</td>
<td>18</td>
<td>7.0E−04</td>
<td>1.2E−02</td>
</tr>
<tr>
<td>Recurrence at 3 years [Sorlie et al. (49)]</td>
<td>18</td>
<td>7.0E−04</td>
<td>1.2E−02</td>
</tr>
<tr>
<td>Recurrence at 3 years [Loi et al. (51)]</td>
<td>52</td>
<td>9.8E−04</td>
<td>1.6E−02</td>
</tr>
<tr>
<td>Metastatic event at 1 year [Desmedt et al. (50)]</td>
<td>26</td>
<td>1.0E−03</td>
<td>1.7E−02</td>
</tr>
<tr>
<td>Recurrence at 3 years [Desmedt et al. (50)]</td>
<td>26</td>
<td>1.0E−03</td>
<td>1.7E−02</td>
</tr>
<tr>
<td>Metastatic event at 5 years [Minn et al. (37)]</td>
<td>9</td>
<td>2.0E−03</td>
<td>2.2E−02</td>
</tr>
<tr>
<td>Metastatic event at 5 years (van’t Veer et al.)</td>
<td>37</td>
<td>2.0E−03</td>
<td>2.9E−02</td>
</tr>
<tr>
<td>Dead at 3 years [van de Vijver et al. (52)]</td>
<td>44</td>
<td>3.0E−03</td>
<td>3.6E−02</td>
</tr>
<tr>
<td>Dead at 5 years [Sotiriou et al. (53)]</td>
<td>25</td>
<td>3.0E−03</td>
<td>3.6E−02</td>
</tr>
<tr>
<td>Metastatic event at 5 years [Chin et al. (30)]</td>
<td>49</td>
<td>3.0E−03</td>
<td>3.7E−02</td>
</tr>
<tr>
<td>Dead at 3 years [Esserman et al. (31)]</td>
<td>28</td>
<td>6.0E−03</td>
<td>5.8E−02</td>
</tr>
<tr>
<td>Dead at 1 year [Bild et al. (29)]</td>
<td>33</td>
<td>7.0E−03</td>
<td>6.3E−02</td>
</tr>
<tr>
<td>Dead at 3 years [Boersma et al. (47)]</td>
<td>40</td>
<td>7.0E−03</td>
<td>6.6E−02</td>
</tr>
<tr>
<td>Metastatic event at 5 years [Bos et al. (44)]</td>
<td>48</td>
<td>7.0E−03</td>
<td>6.6E−02</td>
</tr>
</tbody>
</table>
peptide was capable of inhibiting the growth of SKR6LR cells (Fig. 2D) and provoking massive apoptosis in these same lapatinib-resistant cells (Fig. 4). Although SKR6LR cells are completely resistant to growth inhibition by lapatinib, continued application of lapatinib in combination with IKK inhibition is required for growth inhibition and the induction of apoptosis. The requirement for continued HER2 blockade in HER2-directed drug-resistant cells is consistent with common clinical practice. New drugs given to patients with advanced HER2-positive breast cancer resistant to the HER2 inhibitor trastuzumab are added to, rather than substituted for, trastuzumab. Clinical trials with level 1 data demonstrate the superiority of continuing trastuzumab in combination rather than switching to an entirely new drug in metastatic breast cancer that has become resistant to trastuzumab (54).

This finding is consistent with activation of parallel growth signaling pathways in acquired resistance to HER2 blockade. If the blockade is lifted, cancer cells are again able to use HER2 signaling to promote growth. The concept of signal transduction along parallel growth factor pathways was recently suggested as a drug resistance mechanism (14). Overexpression of the receptor tyrosine kinase HGF/MET or amplification of the HGF/MET gene is commonly observed in gefitinib-resistant non–small cell lung cancer and trastuzumab-resistant metastatic breast cancer (55). Similarly, Azuma and colleagues proposed a mechanism that involves switching addiction from the HER2 to the FGFR2 pathway, making cancer cells resistant to lapatinib (56). Because many of these upstream parallel pathways may funnel growth signals through IKK, this downstream kinase emerges as a logical target for inhibition, particularly in cells resistant to inhibitors that act on upstream signaling targets.

Lapatinib is a small-molecule inhibitor of EGFR and HER2-linked tyrosine kinases. Trastuzumab results in HER2 internalization and degradation, and may exert an immune-dependent mode of action as well. Both HER2 inhibitors are effective in a proportion of patients with HER2-positive breast cancer but result in treatment resistance in many patients who initially respond (56). The results of our study suggests that drug resistance to HER2 inhibition and the consequent recruitment of upstream receptor tyrosine kinase signaling may be overcome by blocking the NF-κB activation at the level of IKK while maintaining the inhibition of HER2. This strategy may be an alternative for patients who are resistant to anti-HER2 treatment.

Both HER2 and NF-κB are antiapoptotic. Rapidly growing human cancers frequently contain a high fraction of apoptotic cells. Xenografts produced from SKR6 cells consistently harbor apoptotic fractions that exceed 50% (Fig. 3). This is in striking contrast to xenografts generated from SKR6CA in which NF-κB is constitutively active and SKR6LR, which acquired high levels of NF-κB activation after selection for lapatinib resistance. In xenografts from both of these cell lines, apoptotic fractions are consistently below 10% despite large areas of tumor necrosis (Fig. 3 and Supplementary Fig. S3). These findings are consistent with the activation of NF-κB and the induction of antiapoptotic gene products. Induction of NF-κB in tumors potentially is a powerful strategy that allows HER2-positive cancers to avoid apoptosis after inhibition of HER2 signaling and potentially after cytotoxic chemotherapy.

We examined the gene expression profiles in SKR6 derivatives. Expression of active NF-κB induced an antiapoptotic gene program in both SKR6CA and SKR6LR cells (Fig. 5C) and is likely responsible for the profound reduction in the apoptotic fraction observed in xenografts grown from these cells. To test whether the overexpressed antiapoptotic genes found in cluster I from Fig. 5B are clinically relevant, we examined publicly available datasets and found that enrichment of cluster I gene expression is predominantly observed in HER2-positive and triple-negative breast cancers. ER-positive cancers are quite distinct in their pattern of expression for cluster 1 genes (Fig. 5). We simply dichotomized the cluster 1 signature around its mean and examined HER2-positive and triple-negative tumors from patients available in the Kao dataset (Fig. 6; ref. 33). Patients whose tumors expressed a high cluster 1 signature had a poorer overall survival than those whose tumors expressed a lower cluster 1 signature, and patients with a high cluster 1 signature were more apt to having deleterious outcomes (Fig. 6D and Table 1).

Our results demonstrate that NF-κB activation is downstream of HER2 signaling and potentially a mechanism for drug resistance and accelerated tumor growth. This concept is supported by engineering activated NF-κB and selecting lapatinib resistance, two independent strategies that both result in NF-κB hyperactivation. Activated NF-κB induces a gene expression profile that includes antiapoptotic genes, and the antiapoptotic state in tumors, whether a cause or consequence of drug resistance, results in poor patient prognosis (Supplementary Fig. S7). Recent reports suggest, in addition to its role in cell survival, death, inflammation, and immunity, NF-κB activation also regulates the renewal of breast cancer stem cells and plays a key role in chemoresistance (57). We propose that breast cancers resistant to HER2-directed therapies may be susceptible to treatments that include NF-κB inhibition and continued HER2 suppression. Development of effective and clinically useful NF-κB inhibitors is a priority.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

In Memoriam
This article is dedicated in memory of the late Dr. Edward Fox, Director of the Dana-Farber Cancer Institute Molecular Core facilities.

Authors’ Contributions
Conception and design: P.L. Miron, Y.J. Choi, M. Brown, J.D. Iglehart, D.K. Biswas
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc): S.T. Bailey, Y.J. Choi, S.J. Rodig, R. Tian, K.M. Foley, D.K. Biswas
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S.T. Bailey, P.L. Miron, Y.J. Choi, B. Kochuprakash, S.J. Rodig, M. Brown, D.K. Biswas
NF-κB Activation Underlies Anti-HER2 Resistance

Writing, review, and/or revision of the manuscript: S.T. Bailey, P.L. Miron, Y. Choi, B. Kochupurakkal, M. Brown, J.D. Iglehart, D.K. Biswas

Generating data and development of methods: G. Maulik

Acknowledgments

The authors thank Profs. Arthur B. Pardee and Peter Sicinski of the Cancer Biology Department, Dana-Farber Cancer Institute for reading the article. The authors also thank Dr. Sabina Signoretti for her advice on the use and data analysis in ScanScope (Aperio) and Christine L. Urrut of the Brigham and Women’s Hospital Pathology Core Facility for her technical assistance. Authors are thankful to Drs. Harikrishna Nakshatri and Poornima Bhut-Nakshatri for providing the

retroviral expression vector QCXIP-CAP65 and to Dr. Nicoli Birbuk for his input and data interpretation.

Grant Support

This study was supported by funds from Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, by the Eileen and Mark Epstein Family Fund, and by funds from the NCI SPORE in Breast Cancer at Dana-Farber Cancer Institute (P50CA89303). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 26, 2013; revised October 29, 2013; accepted November 2, 2013; published OnlineFirst December 6, 2013.


NF-κB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth

Shannon T. Bailey, Penelope L. Miron, Yoon J. Choi, et al.